VIMTALABSVimta Labs Limited
Healthcare · Diagnostics & Research · NSE · as of 2026-07-20 (delayed ~30 min in market hours)
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on VIMTALABS — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Risk gate: safety score is only 27/100 — volatility, drawdown or liquidity is too poor for a buy call, whatever the chart says
- • Dividend yield: 0.35%
- • MACD: bearish
- • Price vs EMA21: below
- • 1-month return: -7.2%
Bull case
- • Revenue growth: 16.5% YoY
- • ROE: 18.6%
- • ROCE: 23.2%
- • Price vs SMA50: above
Bear case
- • Dividend yield: 0.35%
- • MACD: bearish
- • Price vs EMA21: below
- • 1-month return: -7.2%
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Momentum is fading versus the broader market
- • Dividend yield: 0.35%
- • MACD: bearish
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹23.94). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.